EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CAFs Homologous Biomimetic Liposome Bearing BET Inhibitor and Pirfenidone Synergistically Promoting Antitumor Efficacy in Pancreatic Ductal Adenocarcinoma

Yin Zhang iD, Ranran Yu, Cheng Zhao, Jiawei Liang, Yixuan Zhang iD, Haochen Su, Jing Zhao, Hao Wu, Shijin Xu, Ziying Zhang, Lei Wang, Xiaoping Zou und 3 weitere

Advanced Science · 2024

DOI: 10.1002/advs.202305279 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Yin Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu Province,…. Hauptthemen laut MEDLINE: Cancer-Associated Fibroblasts, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Antineoplastic Agents. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Jiangsu Provincial Double-Innovation Doctor Program, General Project of Nanjing Medical Science and Technology Development Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BRD4 is a member of the BET protein family involved in chromatin remodeling and transcriptional regulation. Several BET inhibitors (BETi) have entered clinical trials, demonstrating potential in inducing cancer cell apoptosis and tumor regression. However, resistance to BETi is common in solid tumors. In pancreatic cancer, it is found that cancer‐associated fibroblasts (CAFs) in the tumor microenvironment reduce the BET inhibitor JQ1 sensitivity by inducing BRD4 expression. Moreover, CAFs play a crucial role in the formation of a dense stromal barrier. Therefore, targeting CAFs in the tumor microenvironment of pancreatic cancer not only enhances cancer cells sensitivity to JQ1 but also increases drug perfusion and improves oxygen supply, thus reducing glycolysis and limiting energy supply. To address this challenge, a homologous targeting mechanism utilizing activated fibroblast membrane‐coated liposomes is proposed for specific drug precise target to CAFs‐rich pancreatic cancer. Additionally, TAT peptides enable liposomes penetration, delivering PFD for targeted anti‐fibrotic therapy, reducing extracellular matrix generation and glycolysis, and enhancing JQ1 delivery and sensitivity. In conclusion, the findings indicate the tremendous potential of this CAFs‐targeting liposomal delivery system in pancreatic cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer-Associated FibroblastsPancreatic NeoplasmsCarcinoma, Pancreatic DuctalAntineoplastic AgentsHumansLiposomesNuclear ProteinsBiomimeticsCell Line, TumorTranscription FactorsTumor MicroenvironmentBromodomain Containing ProteinsCell Cycle ProteinsPyridones

Stichwörter der Autor:innen

cancer-associated fibroblastsnano delivery systempancreatic cancertumor microenvironment

Substanzen

LiposomesNuclear ProteinsTranscription FactorsAntineoplastic AgentsBromodomain Containing ProteinsCell Cycle ProteinspirfenidonePyridonesBRD4 protein, human

Autor:innen und Institutionen

  • Department of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu Province, 210008, P. R. China.
  • Institute of Pancreatology, Nanjing University, Nanjing, Jiangsu Province, 210008, P. R. China.
  • State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences Nanjing University, Nanjing, Jiangsu Province, 210008, P. R. China.
  • Department of Gastroenterology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu Province, 210008, P. R. China.
  • Department of Gastroenterology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province, 210008, P. R. China.
  • Department of Pharmacy, Nanjing Drum Tower Hospital, Drum Tower Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu Province, 210008, P. R. China.

ORCID-Profile: Yin Zhang, Yixuan Zhang, Shu Zhang, Ying Lv

Förderung

  • National Natural Science Foundation of China
  • Jiangsu Provincial Double-Innovation Doctor Program
  • General Project of Nanjing Medical Science and Technology Development Project
  • Nanjing Medical Science and Technology Development Key Project
  • Nanjing Science and Technology project
  • Nanjing Health and Technology development
  • Nanjing Drum Tower Hospital Clinical Research Project

Zitieren

APA

Zhang, Y., Yu, R., Zhao, C., Liang, J., Zhang, Y., Su, H., Zhao, J., Wu, H., Xu, S., Zhang, Z., Wang, L., Zou, X., Zhu, Y., Zhang, S., & Lv, Y. (2024). CAFs Homologous Biomimetic Liposome Bearing BET Inhibitor and Pirfenidone Synergistically Promoting Antitumor Efficacy in Pancreatic Ductal Adenocarcinoma. Advanced Science. https://doi.org/10.1002/advs.202305279

Vancouver

Zhang Y, Yu R, Zhao C, Liang J, Zhang Y, Su H, et al. CAFs Homologous Biomimetic Liposome Bearing BET Inhibitor and Pirfenidone Synergistically Promoting Antitumor Efficacy in Pancreatic Ductal Adenocarcinoma. Advanced Science. 2024. doi:10.1002/advs.202305279

BibTeX
@article{Zhang2024,
  author = {Zhang, Yin and Yu, Ranran and Zhao, Cheng and Liang, Jiawei and Zhang, Yixuan and Su, Haochen and Zhao, Jing and Wu, Hao and Xu, Shijin and Zhang, Ziying and Wang, Lei and Zou, Xiaoping and Zhu, Yun and Zhang, Shu and Lv, Ying},
  title = {CAFs Homologous Biomimetic Liposome Bearing BET Inhibitor and Pirfenidone Synergistically Promoting Antitumor Efficacy in Pancreatic Ductal Adenocarcinoma},
  journal = {Advanced Science},
  year = {2024},
  doi = {10.1002/advs.202305279}
}
Kostenlos starten →